Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity
- 1 October 2004
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 24 (19) , 8541-8555
- https://doi.org/10.1128/mcb.24.19.8541-8555.2004
Abstract
Tumor necrosis factor alpha (TNF-α)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF-α family of death receptor ligands and holds great therapeutic potential as a tumor cell-specific cytotoxic agent. Using a panel of established tumor cell lines and normal cells, we found a significant difference between the number of TRAIL-sensitive cells expressing high levels of c-myc and TRAIL-resistant cells expressing low levels of c-myc (P < 0.05, n = 19). We also found a direct linear correlation between c-myc levels and TRAIL sensitivity in TRAIL-sensitive cell lines (r = 0.94, n = 6). Overexpression of c-myc or activation of a myc-estrogen receptor (ER) fusion sensitized TRAIL-resistant cells to TRAIL. Conversely, small interfering RNA (siRNA)-mediated knockdown of c-myc significantly reduced both c-myc expression and TRAIL-induced apoptosis. The gene encoding the inhibitor of caspase activation, FLICE inhibitory protein (FLIP), appears to be a direct target of c-myc-mediated transcriptional repression. Overexpression of c-myc or activation of myc-estrogen receptor (ER) decreased FLIP levels both in cell culture and in mouse models of c-myc-induced tumorigenesis, while knocking down c-myc using siRNA increased FLIP expression. Chromatin immunoprecipitation and luciferase reporter analyses showed that c-myc binds and represses the human FLIP promoter. c-myc expression enhanced TRAIL-induced caspase 8 cleavage and FLIP cleavage at the death-inducing signaling complex. Combined siRNA-mediated knockdown of FLIP and c-myc resensitized cells to TRAIL. Therefore, c-myc down-regulation of FLIP expression provides a universal mechanism to explain the ability of c-myc to sensitize cells to death receptor stimuli. In addition, identification of c-myc as a major determinant of TRAIL sensitivity provides a potentially important screening tool for identification of TRAIL-sensitive tumors.Keywords
This publication has 76 references indexed in Scilit:
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesisOncogene, 2002
- Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1Oncogene, 2001
- Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during LymphomagenesisMolecular and Cellular Biology, 2001
- Selective Expression of FLIP in Malignant Melanocytic Skin LesionsJournal of Investigative Dermatology, 2001
- Myc Potentiates Apoptosis by Stimulating Bax Activity at the MitochondriaMolecular and Cellular Biology, 2001
- Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of NeurotoxicityBiochemical and Biophysical Research Communications, 1999
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- MycN and IFNγ cooperate in apoptosis of human neuroblastoma cellsOncogene, 1998
- The Pathogenesis of Burkitt's LymphomaPublished by Elsevier ,1990